Ads
related to: pharmacological management multiple sclerosis pdf presentation- Treatment FAQs
See Frequently Asked
Questions. Get The Answers.
- Patient Resources
Download Resources To
Learn More About Treatment.
- Financial Resources
See Financial & Savings Info.
Learn About Savings Options.
- Patient Stories
See What Real Patients
Are Saying About This Treatment.
- Clinical Results
View The Results Of
Clinical Studies Here.
- Relapsing MS Treatment
Learn About A RMS
Treatment Option.
- Treatment FAQs
Search results
Results From The WOW.Com Content Network
Multiple sclerosis can cause a variety of symptoms including changes in sensation (hypoesthesia), muscle weakness, abnormal muscle spasms, impaired movement, difficulties with coordination and balance, problems in speech (known as dysarthria) or swallowing , visual problems (nystagmus, optic neuritis, or diplopia), fatigue and acute or chronic ...
Main symptoms of multiple sclerosis Symptoms and findings in multiple sclerosis. Multiple sclerosis can cause a variety of symptoms varying significantly in severity and progression among individuals: changes in sensation (hypoesthesia), muscle weakness, abnormal muscle spasms, or difficulty moving; difficulties with coordination and balance; problems in speech or swallowing (), visual ...
Tumefactive multiple sclerosis is a condition in which the central nervous system of a person has multiple demyelinating lesions with atypical characteristics for those of standard multiple sclerosis (MS). It is called tumefactive as the lesions are "tumor-like" and they mimic tumors clinically, radiologically and sometimes pathologically.
Multiple sclerosis (MS) is an autoimmune disease resulting in damage to the insulating covers of nerve cells in the brain and spinal cord. [3] As a demyelinating disease , MS disrupts the nervous system's ability to transmit signals , resulting in a range of signs and symptoms , including physical, mental , and sometimes psychiatric problems.
Interferon beta-1b is a cytokine in the interferon family used to treat the relapsing-remitting and secondary-progressive forms of multiple sclerosis (MS). It is approved for use after the first MS event. Closely related is interferon beta 1a, also indicated for MS, with a very similar drug profile.
The earliest clinical presentation of relapsing-remitting multiple sclerosis is the clinically isolated syndrome (CIS), that is, a single attack of a single symptom. During a CIS, there is a subacute attack suggestive of demyelination which should be included in the spectrum of MS phenotypes. [ 13 ]
Ads
related to: pharmacological management multiple sclerosis pdf presentation